| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/03/2011 | EP2350051A1 Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
| 08/03/2011 | EP2350050A1 Process for the preparation of enantiomerically enriched proton pump inhibitors |
| 08/03/2011 | EP2350049A2 P38 map kinase inhibitors |
| 08/03/2011 | EP2350048A2 Azine derivatives and methods of use thereof |
| 08/03/2011 | EP2350047A2 P38 map kinase inhibitors |
| 08/03/2011 | EP2350044A1 Method of inducing negative chemotaxis |
| 08/03/2011 | EP2350042A1 Novel thiophene compounds for use in theraphy |
| 08/03/2011 | EP2350039A1 Viral polymerase inhibitors |
| 08/03/2011 | EP2350038A1 Method for producing phenolphthalein using a heteropolyacid catalyst |
| 08/03/2011 | EP2350032A1 Benzoxazole compounds and methods of use |
| 08/03/2011 | EP2350031A2 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 08/03/2011 | EP2350030A1 Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof |
| 08/03/2011 | EP2350029A1 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| 08/03/2011 | EP2350028A1 Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers |
| 08/03/2011 | EP2350027A1 Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| 08/03/2011 | EP2350026A1 Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine |
| 08/03/2011 | EP2350024A2 Improved process for the preparation of endothelin receptor antagonists |
| 08/03/2011 | EP2350023A1 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors |
| 08/03/2011 | EP2350022A1 New benzimidazole derivatives |
| 08/03/2011 | EP2350021A1 Bridged tetrahydronaphthalene derivatives |
| 08/03/2011 | EP2350020A1 Spiro-imidazolone derivatives as glucagon receptor antagonists |
| 08/03/2011 | EP2350019A1 Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
| 08/03/2011 | EP2350018A1 Histidinol dehydrogenase inhibitors, and use thereof as medicaments |
| 08/03/2011 | EP2350017A1 Amide compounds useful in therapy |
| 08/03/2011 | EP2350016A2 Aryl gpr120 receptor agonists and uses thereof |
| 08/03/2011 | EP2350015A1 Isoquinolinone derivatives as nk3 antagonists |
| 08/03/2011 | EP2350014A1 Glycine b antagonists |
| 08/03/2011 | EP2350012A2 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| 08/03/2011 | EP2350009A1 Sulfonate salts of flupirtine |
| 08/03/2011 | EP2350008A1 Method for the preparation of functionalized trihalomethoxy substituted pyridines |
| 08/03/2011 | EP2350007A1 Heterocyclic antiviral arylpyridone derivatives |
| 08/03/2011 | EP2350006A1 Compounds for inflammation and immune-related uses |
| 08/03/2011 | EP2350005A1 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b |
| 08/03/2011 | EP2350004A1 Compounds for inflammation and immune-related uses |
| 08/03/2011 | EP2350003A1 Substituted disulfonamides as bri-modulators |
| 08/03/2011 | EP2350002A1 Novel compounds as calcium channel blockers |
| 08/03/2011 | EP2350001A1 Novel benzylidene-indolinone and their medical and diagnostic uses |
| 08/03/2011 | EP2350000A1 Piperazine derivatives for binding and imaging amyloid plaques and their use |
| 08/03/2011 | EP2349999A1 Allosteric protein kinase modulators |
| 08/03/2011 | EP2349998A2 A novel process for the preparation of eletriptan |
| 08/03/2011 | EP2349997A1 Atropisomers of (hydroxyalkyl) pyrrole derivatives |
| 08/03/2011 | EP2349996A1 1-phenylpyrrole compounds |
| 08/03/2011 | EP2349995A1 Selective seprase inhibitors |
| 08/03/2011 | EP2349991A1 Transition metal complexes of bis[thiohydrazide amide] compounds |
| 08/03/2011 | EP2349990A1 Aryl-phenyl-sulfonamide-phenylene compounds and their use |
| 08/03/2011 | EP2349989A1 Alkyl sulfosuccinate mixtures, and use thereof |
| 08/03/2011 | EP2349988A1 Organic nutrient salts, methods of preparation and uses |
| 08/03/2011 | EP2349983A2 Difluorphenyl diacylhydrazide derivates |
| 08/03/2011 | EP2349979A2 Tetrahydronaphthalene compounds |
| 08/03/2011 | EP2349964A2 Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds |
| 08/03/2011 | EP2349340A2 Stable aqueous formulations of water insoluble or poorly soluble drugs |
| 08/03/2011 | EP2349337A1 Formulations for the treatment of acute herpes zoster pain |
| 08/03/2011 | EP2349335A1 Levetiracetam immunoassays |
| 08/03/2011 | EP2349334A1 S1p receptor agonists for the treatement of cerebral malaria |
| 08/03/2011 | EP2349322A1 Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities |
| 08/03/2011 | EP2349318A1 Antibiotic synergism |
| 08/03/2011 | EP2349313A1 Combination therapy with peptide epoxyketones |
| 08/03/2011 | EP2349309A1 Pyrazalone derivative formulations |
| 08/03/2011 | EP2349289A1 Pharmaceutical compositions containing diacerein |
| 08/03/2011 | EP2349288A2 Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3) |
| 08/03/2011 | EP2349287A2 Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50- 53. |
| 08/03/2011 | EP2349286A2 Method for apcdd1 mediated regulation of hair growth and pigmentation and mutants thereof |
| 08/03/2011 | EP2349285A2 Methods for treating or preventing pain using spicamycin derivatives |
| 08/03/2011 | EP2349284A1 Methods and compositions for treatment of acute heart failure |
| 08/03/2011 | EP2349283A2 Triperpenoid 2-deoxy glycosides and use thereof as medicaments |
| 08/03/2011 | EP2349282A2 Methods of treating pulmonary disorders with liposomal amikacin formulations |
| 08/03/2011 | EP2349281A1 Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition |
| 08/03/2011 | EP2349280A1 Methods of treatment of hyperuricemia and associated disease states |
| 08/03/2011 | EP2349279A1 Modulators of aldehyde dehydrogenase and methods of use thereof |
| 08/03/2011 | EP2349278A1 Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections |
| 08/03/2011 | EP2349277A2 Methods of identification of novel ligands for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (nr1f3) activity |
| 08/03/2011 | EP2349276A2 Hiv integrase inhibitors |
| 08/03/2011 | EP2349275A1 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| 08/03/2011 | EP2349274A1 Folate receptor binding conjugates of antifolates |
| 08/03/2011 | EP2349273A1 Modulators of cxcr7 |
| 08/03/2011 | EP2349272A1 Antiprolactinic veterinary composition for ruminants |
| 08/03/2011 | EP2349271A2 Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| 08/03/2011 | EP2349270A1 2,5-disubstituted morpholine orexin receptor antagonists |
| 08/03/2011 | EP2349269A1 2,5-disubstituted piperidine orexin receptor antagonists |
| 08/03/2011 | EP2349268A1 3, 3', 4, 4'-tetrahydroxy-2, 2'-bipyridine-n, n'-dioxides for the treatment of renal cell carcinoma |
| 08/03/2011 | EP2349267A1 Pyridazine carboxamide orexin receptor antagonists |
| 08/03/2011 | EP2349266A1 Sulfonamide containing compounds and uses thereof |
| 08/03/2011 | EP2349265A1 Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent |
| 08/03/2011 | EP2349264A1 Pyrimidinium derivatives for use in the treatment or prevention of diabetes |
| 08/03/2011 | EP2349263A2 Modulators of cystic fibrosis transmembrane conductance regulator |
| 08/03/2011 | EP2349262A1 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| 08/03/2011 | EP2349261A2 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 08/03/2011 | EP2349260A1 Janus kinase inhibitors for treatment of dry eye and other eye related diseases |
| 08/03/2011 | EP2349259A1 Inhibitors of mitosis for increasing apoptosis in therapy |
| 08/03/2011 | EP2349258A1 Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof |
| 08/03/2011 | EP2349257A1 Use of paf receptor for treating infections caused by flaviviridae |
| 08/03/2011 | EP2349256A1 Heterocyclic benzimidazoles as trpm8 modulators |
| 08/03/2011 | EP2349255A1 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| 08/03/2011 | EP2349254A2 Skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases containing ortho-dihydroxyisoflavone derivatives |
| 08/03/2011 | EP2349253A1 Use of dianhydrohexite mononitrate derivatives as healing agents |
| 08/03/2011 | EP2349252A2 Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents |
| 08/03/2011 | EP2349251A1 Topical formulations with a tertiary amine oxide |
| 08/03/2011 | EP2349250A1 Fatty acids for use as a medicament |
| 08/03/2011 | EP2349249A2 Synergistic composition for recovery and reduction of mild ischemic damage |
| 08/03/2011 | EP2349248A2 Topical nsaid compositions having sensate component |